Please use this identifier to cite or link to this item:
Title: Lapatinib, a dual inhibitor of ErbB-1/-2 receptors, enhances effects of combination chemotherapy in bladder cancer cells.
Authors: McHugh, Lynsey A.
Sayan, A. Emre
Mejlvang, Jakob
Leyshon Griffiths, T. R.
Sun, Yiyang
Manson, Margaret M.
Tulchinsky, Eugene M.
Kilian Mellon, J.
Kriajevska, Marina
First Published: Apr-2009
Publisher: Spandidos Publications
Citation: International Journal of Oncology, 2009, 34 (4), pp. 1155-1163.
Abstract: Survival rate of patients diagnosed with the invasive form of bladder cancer is low suggesting an urgent need to implement novel treatments. GTC (gemcitabine, paclitaxel and cisplatin) is a new chemotherapeutic regimen, which has shown promise in clinical trials. Given that receptor tyrosine kinases of the ErbB family are overexpressed in a high proportion of metastatic bladder tumours, approaches involving small-molecule inhibitors of ErbB receptors in combination with conventional cytostatic drugs are of potential interest. Here, we show that the dual inhibitor of ErbB receptors, lapatinib, enhances cytostatic and induces cytotoxic effects of GTC in two bladder cancer cell lines which differ with regard to expression levels of proteins taking part in the ErbB pathway. Lapatinib inhibited phosphorylation of ErbB receptors and also reduced the level of phosphorylated AKT. Flow cytometry analysis demonstrated that GTC treatment affects cell cycle distribution differently in the presence or absence of lapatinib. In RT112 cells, which express high levels of ErbB receptors and harbour wild-type p53, combined GTC/lapatinib treatment resulted in the phosphorylation of p53 at Ser46 and accumulation of sub-G1 cell populations. Our data indicate that a combinatorial approach involving GTC and lapatinib may have therapeutic potential in a subset of bladder tumours depending on the genetic context.
DOI Link: 10.3892/ijo_00000244
ISSN: 1019-6439
Type: Article
Rights: This paper was published as International Journal of Oncology, 2009, 34 (4), pp. 1155-1163. It is available from Doi: 10.3892/ijo_00000244
Appears in Collections:Published Articles, Dept. of Cancer Studies and Molecular Medicine

Files in This Item:
File Description SizeFormat 
ijo_34_4_1155_PDF published.pdf524.67 kBAdobe PDFView/Open

Items in LRA are protected by copyright, with all rights reserved, unless otherwise indicated.